Table 4 PRNT50 GMTs against SARS-CoV-2 variants (12 months post 2nd dose or 6 months post third dose, day 395).

From: Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants

 

Geometric mean titer (95% CI)

Seroconversion ratea (95% CI)

Booster

Non-booster

Booster

Non-booster

D614G (NIV-770-2020)

N = 31

178.9

(82.6–387.5)

N = 37

10.7

(2.6–44.5)

30/31

96.8%

(81.5–99.8)

22/37

59.5%

(42.2–74.8)

Delta (B.1.617.2)

N = 31

115.9

(55.8–240.8)

N = 37

7.3

(2.0–27.0)

30/31

96.8%

(81.5–99.8)

22/37

59.5%

(42.2–74.8)

Omicron (B.1.1.529)

N = 31

25.7

(13.0–50.6)

N = 37

2.9

(0.99–8.3)

29/31

93.5%

(77.2–98.9)

21/37

56.8%

(39.6–72.5)

  1. aDefined as a post-vaccination IgG titer that was at least fourfold higher than the baseline titer.
Back to article page